CGRP as the target of new migraine therapies — successful translation from bench to clinic You can now download the document here: —–> CGRP as the target of new migraine therapies — successful translation from bench to clinic Treatment of migraine is on the cusp of a new era with the development of drugs that target …
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar …
New measures to avoid valproate exposure in pregnancy Read More »
The European Medicines Agency’s experts in medicines safety, the Pharmacovigilance Risk Assessment Committee (PRAC) are recommending new measures to avoid exposure of babies to valproate medicines in the womb. Babies exposed are at risk of malformations and developmental problems. The PRAC examined the available evidence and consulted widely with healthcare professionals and with patients, including women …
PRAC recommends new measures to avoid valproate exposure in pregnancy Read More »
Laboratory-made antibody Erenumab blocks neural brain pathway and is first new treatment for attacks approved in 20 years A new migraine drug that can halve the length of time sufferers are laid low by the debilitating condition has been hailed as an “incredibly important” advance. Erenumab, a laboratory-made antibody that blocks a neural brain pathway …
New Migraine drug hailed as “Incredibly important” breakthrough Read More »
European Federation of Neurological Associations Training initiatives for neurology advocates❕❕ EFNA´s Training initiatives in SPAIN #campusdiversia#EMHAumbrella The 26th 27th of October 2017, the European Federation of Neurological associations develop together with the support of Elena Ruiz de la Torre, president of European headache alliance, an extraordinary Training initiative for Neurological Associations in Valencia ,Spain. This …
Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of …
Positive Phase III data for migraine drug Fremanezumab Read More »
OBJECTIVES: The aim of this study was to evaluate the efficacy of greater occipital nerve (GON) block in the treatment of migraine patients. METHODS: This study included 28 patients diagnosed with migraine between 2014 and 2015. The GON block procedure was applied by administering 1.5 ml of 2% lidocaine 2 cm lateral and 2 cm …
The results of greater occipital nerve block applied for migraine headache Read More »
Patients with chronic migraine share features with individuals with temporomandibular disorders that include kinesiophobia and neck disability, according to a cross-sectional study recently published in Pain Medicine.1 A growing body of research indicates a number of shared features between chronic migraine and TMD. For example, patients with chronic migraine, but not headache-free individuals, commonly experience …
Disability & Catastrophizing In Chronic Migraine vs Temporomandibular Disorder Read More »
